Leslie Brent Laboratory Title: Leslie Brent Laboratory Therapeutic Drug

Service Monitoring User Guide

QMS Index No. IS001

Author: Gary Chusney & Janet Lee

Authorised: Tom Cairns

Version: 13 **Date of issue:** 14/04/2023

Page 1 of 11

LESLIE BRENT LABORATORY

ICHNT Renal & Transplant Centre Imperial College Healthcare NHS Trust London, W12 0HS

LESLIE BRENT LABORATORY THERAPEUTIC DRUG MONITORING SERVICE USER GUIDE

VERSION No	13
DATE OF ISSUE	14/04/2023
AUTHOR	Gary Chusney & Janet Lee
AUTHORISED BY	Janet Lee
REVIEW INTERVAL	Two Yearly
COPY No	1 of 3
LOCATION OF AUTHORISED COPIES	 S:\Renal – LBL Restricted\Active QM Documents Laboratory Office ICHNT Intranet

Leslie Brent Laboratory Title: Leslie Brent Laboratory Therapeutic Drug

Service Monitoring User Guide

QMS Index No. IS001

Author: Gary Chusney & Janet Lee

Authorised: Tom Cairns


Version: 13 **Date of issue:** 14/04/2023 **Page** 2 of 11

1. INTRODUCTION

The Leslie Brent Laboratory is part of the Department of Renal and Transplant Medicine within the Division of Medicine and Integrated Care (MIC) and part of Imperial College Healthcare NHS Trust (ICHNT). The laboratory provides a Therapeutic Drug Monitoring Service (TDM) for prescribed immunosuppressive/immunomodulatory drugs in adult and paediatric patients. Selective and sensitive detection is via liquid chromatography with tandem mass-spectrophotometric detection (LC-TMS) where service provision currently includes the following; Tacrolimus, Ciclosporin, Mycophenolic Acid (MPA), Sirolimus, five anti-fungal drugs; 5-flucytosine, Itraconazole, Hydroxy-itraconazole, Posaconazole, and Voriconazole and the immuno-modulatory compound Hydroxychloroquine (HCQ).

2. LOCATION

The Leslie Brent Laboratory is situated on the ground floor of the Renal building (F block) at Hammersmith Hospital, Du Cane Road, London.



3. CONTACT DETAILS FOR RESULTS, ADVICE & SUPPORT

Address: Leslie Brent Laboratory

Ground Floor

West London Renal & Transplant Centre Imperial College Healthcare NHS Trust

Hammersmith Hospital

Du Cane Round

W12 0HS



Leslie Brent Laboratory Title: Leslie Brent Laboratory Therapeutic Drug QMS Index No. IS001

Service Monitoring User Guide

Author: Gary Chusney & Janet Lee Authorised: Tom Cairns

Dr. Tom Cairns Laboratory Director 07958468693 (Mobile)
Dr. Janet Lee Laboratory Manager 020 331 36639
Enquiries/Results 020 331 36637
Fax to E-mail (From Sender) 020 331 36640

E-mail <u>imperial.leslie.brentlab@nhs.net</u>

4. COMPLAINTS OR CONCERNS

Should the need arise to lodge a complaint related to the Leslie Brent Laboratory, please contact the Laboratory Manager via telephone on 020 331 36639 or via email imperial.leslie.brentlab@nhs.net. Alternatively contact PALS via telephone 020 331 30088, Monday to Friday, 09:30-17.00 or via email imperial.pals@nhs.net. All concerns (complaints will be promptly responded to in line with Trust and Leslie Brent Laboratory policies and procedures.

5. CONFIDENTIALITY AND THE PROTECTION OF PERSONAL INFORMATION

Imperial College Healthcare NHS Trust is committed to delivering a first class confidential service ensuring that all patient information is processed fairly, lawfully and transparently. Confidential information about patients can only be used for healthcare and relevant business purposes. All Trust staff follow the Trust Information Security Policy. The Trust has also issued Confidentiality Guidance for staff which is available via the Trust Intranet. In addition to this, all Health and Care Professions Council (HCPC) registered staff follow the HCPC confidentiality guidance for registrants.

6. LABORATORY OPENING TIMES (OUT OF HOURS, BANK HOLIDAYS)

Normal opening hours are 09:00 to 17:00, Monday to Friday. Only one day during each Bank holiday weekend is covered. There is **no** routine provision for an on-call/out-of-hours service.

These information can also be obtained from visiting Leslie Brent Laboratory (intranet) or from Internet- Leslie Brent Laboratory (https://www.imperial.nhs.uk/our-services/kidney-and-transplant/kidney-care-in-north-west-london/leslie-brent-laboratory).

7. TESTS PROVIDED

Hospitals within the Trusts' network should request tests via Cerner using the specific drug name and sent to the Leslie Brent Laboratory, Hammersmith Hospital. If on site at Hammersmith these can be sent directly, via Pod 701. Alternatively they should be sent via Pathology Specimen Reception who will forward on. For requests from departments outside of the Trust's network, samples can be sent directly to the address given in Section 3 and in accordance with test and transport requirements given in Sections 10 & 11. For turnaround times refer to Section 13.

Leslie Brent Laboratory Title: Leslie Brent Laboratory Therapeutic Drug QMS Index No. IS001

Service Monitoring User Guide

Author: Gary Chusney & Janet Lee Authorised: Tom Cairns

Version: 13 **Date of issue:** 14/04/2023 **Page** 4 of 11

The tests below are performed on the following days:

Ciclosporin whole blood levels (Monday to Friday)

- Tacrolimus whole blood levels (Monday to Friday)
- Mycophenolic Acid (MPA) plasma levels (2 times per week)
- Sirolimus whole blood levels (1 2 times per week depending on demand)
- Anti-fungal drug plasma levels (Voriconazole, Itraconazole/Hydroxyitraconazole, Posaconazole and 5-Flucytosine) – (Tuesday and Friday's only)*
- Hydroxychloroquine (Every 2 weeks)

*To ensure results are reported on Tuesday and Friday, samples should ideally arrive by 4:30pm the previous day or by 10am on the day. Where there is a request for either Hydroxyitraconazole (the main metabolite with pharmacological activity) or Itraconazole, both results will be reported – Refer to Section 13 for Trust therapeutic ranges.

Please indicate if the patient is on Atazanavir if taking Itraconazole, is on Ritonavir if taking Hydroxyitraconazole, and is on Metformin, Vigabatrin or Emtricitabin if taking 5-Flucytosine.

8. SAMPLE REQUIRED (PER TEST)

For the immunosuppressant drugs a single blood sample is taken just before the subsequent dose (trough level) and at a constant interval; **12h** for Tacrolimus (Prograf/Adoport), Ciclosporin and Mycophenolate; **24h** for Tacrolimus (Advagraf) and Sirolimus from the time of the previous dose. Section 13 lists the sample tube type for each test whilst below gives the minimum volume of blood required to perform each test.

- Ciclosporin / Tacrolimus / Sirolimus: EDTA-anti-coagulated whole blood (0.5ml to 2ml)
- Mycophenolic Acid (MPA): EDTA-anti-coagulated whole blood bottle "Purple Top" (0.5ml to 2ml, preferred 1ml).
- For anti-fungal drug monitoring a pre-dose trough level should always be taken within 1 hour prior to the time that the dose is due. 5-Flucytosine also requires a 1 hour POST dose level
- Voriconazole / Posaconazole / Itraconazole / Hydoxyitraconazole / 5-Flucytosine: red plain top blood bottle (plain clotted, not serum separator tubes [SST]) or EDTA-anticoagulated whole blood bottle "Purple Top" (0.5 to 2ml)
- Other types of blood collection tubes are not suitable and cannot be used

 Refer to Trust guideline 'Anti-fungal Guidelines For Adults, Paediatrics and Neonates'
 from ICHNT intranet
- Hydroxychloroquine (HCQ): EDTA-anti-coagulated whole blood (0.5ml 2ml) (N.B. Fluoride-oxalate anti-coagulated samples CANNOT be used for any assay)

9. REQUESTS FOR TDM TESTING

Each request accepted by the laboratory for examination of the tests given above is considered an agreement to provide services as described in the introduction.

Imperial College Healthcare **NHS**

NHS Trust

Leslie Brent Laboratory Title: Leslie Brent Laboratory Therapeutic Drug

Service Monitoring User Guide

QMS Index No. IS001

Author: Gary Chusney & Janet Lee

Authorised: Tom Cairns

Version: 13 **Date of issue:** 14/04/2023 **Page** 5 of 11

The Leslie Brent Laboratory is responsible for the provision of the requested investigation and will only perform analysis on samples that are in keeping with acceptance and rejection criteria given below. Instructions for sample collection are available on the Leslie Brent Laboratory website:

- OPD Instructions Sample Collection for Therapeutic Drug Monitoring (IS018)
- Inpatient Instructions Sample Collection for Therapeutic Drug Monitoring (IS019)

The laboratory performs examinations that have been assessed and UKAS accredited to Standard ISO15189:2012, the current Schedule of Accreditation can be found on the UKAS website (www.ukas.com) under customer number 9280, Imperial College Healthcare NHS Trust, Leslie Brent Laboratory.

The laboratory may also perform examinations that are non UKAS accredited and will be reported with a statement to the effect of "This is a newly implemented test and is awaiting UKAS assessment" for new methods. Reporting of results on such tests will have followed a period of R&D and agreement, and with the intention of adding the examination as an "Extension to Scope" with UKAS. There may be other situations where the platform may change, an additional matrix has been added, or the test is not accredited. Under these circumstances the following statements will be attached to the report:

"Due to a recent change in analytical platform, this test is not currently UKAS accredited".

"The laboratory is not UKAS accredited for this test on this sample type".

"The laboratory is not UKAS accredited for this test"

All local requests (ICHNT) should be made via Cerner. In the event of Cerner Downtime requests can be made using the Leslie Brent Laboratory Form (Appendix 1) which is available on the Trust Intranet by typing in Leslie Brent Laboratory. For requests for tests external to the Trusts' network of hospitals, a local request form is sufficient but should state contact details of requesting department including email address.

Requests for Tacrolimus Profiles should be discussed with the laboratory prior to collecting and sending samples. Samples should be sent with an appropriate request form and collected as per the instructions stated on Request Form & Instructions (IS011) form – Refer to Appendix 2, which is available on the Leslie Brent Laboratory webpage on the Trust Intranet.

It is imperative that the correct patient is selected on the local electronic ordering system to ensure that the correct result is being issued on the correct patient. If an error is made, contact the Leslie Brent Laboratory on 0203 313 6637 as soon as possible.

It is the responsibility of the requesting doctor completing the request form or sample label to ensure that sufficient information is provided and that all information is correct, even if these duties are delegated. The onus is not on the laboratory to make assumptions about the origins or nature of specimens or the accuracy of any given details. If the information given is inadequate to process the request then delays may occur or the request may be rejected/returned to the sender. Every effort will be made to ensure that specimens are processed correctly and that vital specimens are not discarded, but if the integrity of the information provided or the source of a specimen cannot be fully established the sample will have to be discarded.



Page 6 of 11

Leslie Brent Laboratory Title: Leslie Brent Laboratory Therapeutic Drug

Service Monitoring User Guide

QMS Index No. IS001

Author: Gary Chusney & Janet Lee

Authorised: Tom Cairns

Version: 13 **Date of issue:** 14/04/2023

Space is available on the request forms for the following information which the referrers should provide:

- The patient's Forename, Surname and Date of Birth
- The patient's Hospital number or NHS number (if available) and their gender
- The test required
- The most recent drug dose (in mg) and the time and date of that dose
- The time and date of the blood sample taken for testing
- The legible Name of the requesting healthcare professional and a contact number
- The clear address to which the report of the result should be sent
- Any other pertinent information e.g., co-medication; liver dysfunction; infection risk

Samples must have

- The patient's Forename and Surname
- Date of Birth
- The patient's Hospital Number or NHS number
- And very importantly the sample date

Leslie Brent Laboratory Sample Acceptance and Rejection Criteria

Acceptance/Rejection Criteria	Action
Unlabelled Sample/Mismatched Sample	Sample will be discarded
Wrong sample container:	Clinic/Ward/Clinic/Requestor will be informed. Can another sample be taken? Is there another suitable
e.g., clotted sample for Ciclosporin, Tacrolimus or Sirolimus	sample available? If yes arrange for collection. IF NOT:
Fluoride/Oxalate for MPA,	The test will be cancelled and a comment added such as
Gel containers for Anti-Fungal Drugs Not enough sample	"No appropriate sample received: please send [insert type of sample required]"
Unlabelled request form (sample is labelled appropriately)	If sufficient information is provided on sample this will transcribed onto the form.
Mismatched information on sample and/or	The sender will be contacted to confirm details are correct
form, e.g., misspelling of name, differences in DoB or Hospital number	if Cerner or other databases are not helpful
Leaking sample:	
Minor leak	If minor leak from non high-risk sample, an attempt to clean it will be made
CO.	If sample is known to be <i>high-risk</i> the sample will be discarded
1100	Clinician/Ward/Clinic or sender if sent by Courier will be informed
Major leak	If significant leak which contaminates other samples and obscures patient information – the samples will be discarded
	Clinician/Ward/Clinic or sender if sent by Courier will be informed
Mismatched information on sample and form, e.g., miss-spelling of name, differences in DoB or Hospital number	The sender will be contacted the sender to confirm details if Cerner or other databases are not helpful
No test indicated on request form or sample	Clinician/Ward/Clinic will be contacted for advice

Leslie Brent Laboratory Title: Leslie Brent Laboratory Therapeutic Drug QMS Index No. IS001

Service Monitoring User Guide

Author: Gary Chusney & Janet Lee Authorised: Tom Cairns

Version: 13 **Date of issue:** 14/04/2023 **Page** 7 of 11

Requests for additional tests must be made directly to the laboratory by the requesting clinician or a senior Clinical Nurse Specialist, within 24 hours of receipt of the original sample and request form.

10. STABILITY

If samples are not transported immediately they should be stored refrigerated, not frozen prior to dispatch. Ideally, plasma for MPA should be separated from blood before dispatch to the laboratory if the sample will not reach us within 24hrs.

11. TRANSPORT OF SAMPLES

Samples from departments external to the Trust should be packaged in accordance with UN Packaging Instructions PI650. This requires that the primary sample container must be leak proof and be wrapped in sufficient absorbent material to absorb any spillage. The primary container and absorbent material must be placed in a single bag with the request form in the pouch. The outer rigid box should have a printed label stating that the content is Category B Biological Substance and is assigned to UN3373. Please contact the Leslie Brent Laboratory, on 0203 313 6637 for further advice and information.

12. REPORTS, CLINICAL SUPPORT, ADVICE & GUIDANCE

Depending on the frequency of analysis – Refer to Section 7, results are usually reported within 24 hours of receipt, this is particularly the case for Ciclosporin and Tacrolimus. Results will be reported as follows:

- Electronically via Cerner or ICE
- Proton (Renal Medicine only)
- By email (preferably sent to NHS.NET but can be sent encrypted to other emails)
- By phone (020 331 36637) but are divulged only to an official healthcare representative of the patient. Please have your / patient identifiers ready
- As printed results (issued by first class mail to referrers by request only)

It is preferable to send results for requests received from outside of the Trust's network of hospitals by email. Reports will be sent as a PDF copy of the result and sent either to NHS.NET email addresses or sent encrypted to other email addresses. There is no facility to send a Faxed report.

The values for immunosuppressant drugs are <u>guidelines only</u> based on LC-TMS methodology and on target levels in use within the Imperial College Renal & Transplant Centre. Laboratory staff are unable to offer clinical advice in relation to drug dose changes.

There are no therapeutic ranges established by this laboratory for these drugs that are applicable to non-renal patients. For clinical interpretation of results contact the patients' senior specialist as this is not provided by the laboratory.

For antifungal drugs, refer to the Trust's 'Anti-fungal Guidelines For Adults, Paediatrics and Neonates' guidelines found on the Trust Intranet.



Leslie Brent Laboratory Title: Leslie Brent Laboratory Immunosuppressive Drug Monitoring User's Guide

QMS Index No. IS001

Author: Gary Chusney

Authorised: Tom Cairns

Version: 12 **Date of issue**: 10/02/2022 **Page** 8 of 11

13. DETAILS OF TESTS PROVIDED

Drug	Sample Type	Container	Turnaround Time from receipt *	Therapeutic Ranges [¥] (NB: Concentration refer to trough samples)	Additional requirements and other comments
Ciclosporin	Whole blood	3.5mL EDTA (purple top)	24hrs	100 - 200μg/L	Trough level sample collected 12hr post dose in morning
Tacrolimus	Whole blood	3.5mL EDTA (purple top)	24hrs	5 - 12μg/L	Trough levels for slow release formulations (e.g. Advagraf) is 24hr post dose, otherwise 12hr post dose (twice daily formulation)
Sirolimus	Whole blood	3.5mL EDTA (purple top)	7days	4 - 20μg/L	Trough level sample collected 24hr post dose in morning
Mycophenolic acid	Plasma	3.5mL EDTA (purple top)	4days	1.2 – 2.4mg/L	Trough level sample collected 12hr post dose in morning
5-Flucytosine	Serum	6mL plain (Red top)	4days	N/A For 5-Flucytosine therapeutic ranges, please discuss this with a specialist infection team	Samples collected in Gold or Rust top SST tubes will not be accepted.
Itraconazole	Serum	6mL plain (Red top)	4days	For range see result for Hydroxyitraconazole	Samples collected in Gold or Rust top SST tubes will not be accepted.
Hydroxyitraconazol e	Serum	6mL plain (Red top)	4days	Prophylaxis: 0.5 -4.0mg/L^ Therapy: 1.0 – 4.0mg/L^	Samples collected in Gold or Rust top SST tubes will not be accepted.
Posaconazole	Serum	6mL plain (Red top)	4days	Prophylaxis: 0.7-1.5mg/L^ Therapy: 1.0- 3.75-mg/L^	Samples collected in Gold or Rust top SST tubes will not be accepted.
Voriconazole	Serum	6mL plain (Red top)	4days	Prophylaxis Trough > or = to 1mg/L ^ Therapy Trough: >1.0 – 2.0mg/L^ Higher target trough level (i.e. > or = 2 mg/L) should be used in complex diseases (e.g. CNS infection, extensive or bulky infection, multifocal or disseminating infection). Dosage adjustments to keep trough levels < or = 5mg/L help minimise drug related toxicity^	Samples collected in Gold or Rust top SST tubes will not be accepted.
Hydroxychloroquine	Whole blood	3.5mL EDTA (purple top)	14 days	Therapeutic range: >0.60mg/L# There is no defined upper limit of a therapeutic range. The lower limit has been described (0.60mg/L#) below which was considered to be therapeutically inadequate.	Trough level sample collected preferably 12hr post dose in morning



Leslie Brent Laboratory

Title: Leslie Brent Laboratory Immunosuppressive Drug Monitoring User's Guide

QMS Index No. IS001

Author: Gary Chusney

Authorised: Tom Cairns

Version: 12 **Date of issue**: 10/02/2022 **Page** 9 of 11

^{*}Numerous variables determine the target drug levels e.g. graft or disease type, time after transplant, co-medication, drug formulation, and clinical and graft function which should be taken into consideration when interpreting results.

[^] Reference: ICHNT guidelines for anti-fungal drugs "Anti-fungal Guidelines For Adults, Paediatrics and Neonates". If levels are outside of this range please see Anti-Fungal Guideline on the intranet or discuss with an infection specialist

[#] Cunha C, et al. Hydroxychloroquine blood concentration in lupus nephritis: a determinant of disease outcome? Nephrol Dial Transplant (2017) 1–7

^{*}This is the time of receipt of the sample within the Leslie Brent Laboratory. Working days only.

Leslie Brent Laboratory Title: Leslie Brent Laboratory Therapeutic Drug

Service Monitoring User Guide

QMS Index No. IS001

Author: Gary Chusney & Janet Lee

Authorised: Tom Cairns

Version: 12 **Date of issue:** 10/02/2022

Page 10 of 11

APPENDIX 1: REQUEST FORM

		Ward:
Burname:		Ext/Bleep/Fax/email:
orename:		Requested By:
Hospital Number:	DOB:	Consultant:
NHS Number:		BLOCK CAPITALS PLEASE
rug One: late Last Dose (dd/mm/yy):		Drug Two: Date Last Dose (dd/mm/yy):
ime Last Dose (hh:mm):	I	Time Last Dose (hh:mm):
collection Date (dd/mm/yy):	I .	Collection Date (dd/mm/yy):
Collection Time (hh:mm):		Collection Time (hh:mm):
Clinical Details: please note any drugs Indica	led by aslerisk here.	
Therapeutic Drug	Monitoring - T	est Requested (Please Tick <mark>T</mark>
☐ Cyclosporine A(CSA/CyA) ^A ☐ Tacrolimus (FK506) ^A P	lease Circle:	Adoport/Prograf or Advagraf
Mycophenolic Acid (MPA) ^A		Please Note:
,		
☐ Sirolimus/Rapamycin ^A		Samples should be taken pre dose such that a TROUGH sample is taken at 8 to 12 hrs post dose or 24hrs if taking Advagraf
☐ Sirolimus/Rapamycin ^A		a TROUGH sample is taken at 8 to 12 hrs post dose or 24hrs if taking Advagraf
☐ Sirolimus/Rapamycin ^A ☐ Hydroxychloroquine (HCQ) ^A		a TROUGH sample is taken at 8 to 12 hrs post dose or 24hrs if taking Advagraf formulation of Tacrolimus or if on Sirolimus. For 5-Flucytosine samples should be taken pre dose then 2hrs after oral dose taken or 30 mins if intravenous dose.
☐ Sirolimus/Rapamycin ^A ☐ Hydroxychloroquine (HCQ) ^A ☐ Voriconazole ^{AA}	aconazole [^]	a TROUGH sample is taken at 8 to 12 hrs post dose or 24hrs if taking Advagraf formulation of Tacrolimus or if on Sirolimus. For 5-Flucytosine samples should be taken pre dose then 2hrs after oral dose taken or
☐ Sirolimus/Rapamycin ^A ☐ Hydroxychloroquine (HCQ) ^A ☐ Voriconazole ^{AA} ☐ Posaconazole ^{AA}	aconazole ^{AA}	a TROUGH sample is taken at 8 to 12 hrs post dose or 24hrs if taking Advagraf formulation of Tacrolimus or if on Sirolimus. For 5-Flucytosine samples should be taken pre dose then 2hrs after oral dose taken or 30 mins if intravenous dose. Contact the laboratory for further details on
☐ Sirolimus/Rapamycin ^A ☐ Hydroxychloroquine (HCQ) ^A ☐ Voriconazole ^{AA} ☐ Posaconazole ^{AA} ☐ *traconazole/**Hydroxy-tra		a TROUGH sample is taken at 8 to 12 hrs post dose or 24hrs if taking Advagraf formulation of Tacrolimus or if on Sirolimus. For 5-Flucytosine samples should be taken pre dose then 2hrs after oral dose taken or 30 mins if intravenous dose. Contact the laboratory for further details on
☐ Sirolimus/Rapamycin ^A ☐ Hydroxychloroquine (HCQ) ^A ☐ Voriconazole ^{AA} ☐ Posaconazole ^{AA} ☐ *ttraconazole/**Hydroxy-ttra ☐ ***5-Flucytosine ^{AA}	⊺Top" ^^ Requ	a TROUGH sample is taken at 8 to 12 hrs post dose or 24hrs if taking Advagraf formulation of Tacrolimus or if on Sirolimus. For 5-Flucytosine samples should be taken pre dose then 2hrs after oral dose taken or 30 mins if intravenous dose. Contact the laboratory for further details on 020 331 36637



Page 11 of 11

Leslie Brent Laboratory Title: Leslie Brent Laboratory Therapeutic Drug

Service Monitoring User Guide

QMS Index No. IS001

Author: Gary Chusney & Janet Lee

Authorised: Tom Cairns

Version: 12 **Date of issue:** 10/02/2022

APPENDIX 2: TACROLIMUS DRUG PROFILE REQUEST FORM & INSTRUCTIONS

Secretarian Regulated Sp Regul	Samples SHOULD be taken at the dated time points to provide meetingsturecute. Each complain is stated to provide meetingsturecute. Each complain is stated to provide meetingsturecute. Each complain is stated to provide meetingsturecute. Each complain is a fine EVR and included apprehiment of the complaint of th			idon Rénal & Transp	bant Centre, Ham mersm bb. ⊓	uest Form & Instructions Hospital, D4 Case Road, W12 DHS			Tacrolimus Pro	ofile Instructions	
Septiments Regarded 59 Consulted Regarded 59 Consulted Regarded 59 Consulted Regarded 59 Regarde	Set	Surnama		(PDZI 331 36637	™ pertal.les lie bre rittab@r	is.iet)	▋▐▐	Leslie Brent L	aboratory staff MUST t	be notified prior to starting	drug profile
NBC The time points in reached are additional time points for when in-polarized are monitored. Place	Requested By Consultry] s	amples SHOULD be taken	at the stated time poin	ts to provide meaningful re	esults. Each sample mu
NB. The time points in brackets are additional time points by "when in-patients are monitored." Percentage of Management of the points to when in-patients are monitored. Percentage of Management of the points to when in-patients are monitored. Percentage of Management of the points to when in-patients are monitored. Percentage of Management of the points to when in-patients are monitored. Percentage of Management of the points to when in-patients are monitored. Percentage of Management o	NB. The filter points in bracelets are additional time points for viven in-patients are monitored. Presented to more plants and present the points of the points in tracelets are additional time points for viven in-patients are monitored. Presented on Once Dallay. PRO-ORF, DALPORT, ENVIRONS (OTHER: Court of the points in the point of the po		ber				a	3.5ml EDTA anti-coagulate	ed whole blood sample	tube "Purple Top" (Minim	um volume 0.5 – 2.0ml
membration (Cite) Twice Daily POCRE, ADOPORT (OTHER more Daily ADVORAF, DALIPORT, ENVESUS) COTHER: Common Daily ADVORAF, DALIPORT, ENVESUS) COTHER: Common Daily ADVORAF, DALIPORT, ENVESUS) COTHER: Common Daily ADVORAF, DALIPORT, ENVESUS (DITTER) Common Daily ADVORAF, DALIPORT, ENVESUS (DITTER) Common Daily ADVORAF, DALIPORT, ENVESUS (DITTER) COMMON DAILY	mentation (Cite) Twice Daily POCRE, ADOPORT (OTHER more Daily ADVORAF, DALIPORT, ENVESUS) (OTHER: The Collab.) ADVORAF, DALIPORT, ENVESUS (OTHER: The Collab.) Advorated to the Collab.		ibei				⊣ II ա	R: The time noints in bred	kets are additional tin	ne noints for when in net	ients are monitored. P
### ADVASRY DATE OF THE POINT CONTROL OF THE POINT	### ADVASRY DATE OF THE POINT CONTROL OF THE POINT CONTROL OF THE POINT OF THE POIN	Gender			Dose						
Is stance. In Not Book on Cares. The Former with LTVs aredstar are very instead within Fig. 11 Ex 15 Life of Int F CRITICAL CONTROL OF THE CASE LIVE OF THE CA	Is taken. Do Not Book on Center. The Former and LTX ancests are required price of the provided price of the sample and have the TIME POINT in the sample was take to the provided price of the price of the provided price of the provided price of the price of the provided price of the price of the provided price of the price of	ormulation	(Circle): Tw ADVAGRAF, D	rice Daily: PRO DAILIPORT, EN	GRAF, ADOPORT (0	OTHER:	s	amples MUST be labelled	with patients' details	full patient name, DOB,	and a registration no
AMPLE DATE THE FORT THE FANGE (6.2.1%) 1 0.0 PREI 1 0.0 PREI 1 0.0 PREI 1 NB Should be Taken at Time Point Zero 1 NB Should be Taken at Time Point Zero 2 0.5 3 10 0 Profiber 0.5 Pr	AMPLE DATE THE FORT THE FANGE (6.2.2.1%) 1 0.0 (PRE) NB Should be Taken at Time Point Zero NB Should be Taken at Time Point Zero Prof Dose O Prof Dose O Prof	c En					is	taken. Do Not Book on C	u) and must be labelle erner.	a with the <u>UATE, TIME</u> al	noi <u>limic Puini</u> tne sa
Time (Pose Given 1 0.5 Net Should be Taken at Time Point Zero 2 0.5 Pro Dose Given 3 0.5 Pro Dose Given 4 0.5 Pro Dose Given 4 1.5 Pro Dose Given 5 2.0 Pro Dose Given 6 2.0 Pro Dose Given 6 3.0 Pro Dose Given 7 0 4.0 Pro Dose Given 9 0 8.0 Pro Dose Given 9 0 8.0 Pro Dose Given 4 0 Pro Dose Given 9 0 8.0 Pro Dose Given 10 0	Time (Pose Given NE) Should be Taken at Time Point Zero 2	AMPLE			TIME TAKEN			ne form must correspond to	othe sample and have	the <u>TIME</u> and <u>TIME POIN</u>	<u>IT</u> the sample was take
Post Dose 0.5 Po	Post Dose 0.5 Po	1		0.0 [PRE]			ш	<i>Advaoraf/Envarsus</i> ∫ ⊺	Profile Time Points ime (Hrs)	<i>Prograf/Adoport Prof</i> Ti	file Time Points me (Hrs)
Post Dose 1 Post Dose 1.5 Post Dose 2 Post Dose 1.5 Post Dose 2 Post Dose 2.5 Post Dose 2.5 Post Dose 2.5 Post Dose 3.6 Post Dose 4.6 Post Dose 6.6 Post Dos	Post Dose 1 Post Dose 1.5 Post Dose 2 Post Dose 1.5 Post Dose 2 Post Dose 2.5 Post Dose 3 Post Dose 2.5 Post Dose 3 Post Dose 3.5 Post Dose 6 Post Dose 6.6 Post Dose 6 Post Dose 6.7 Post Dose 6 Post Dose 6.7 Post Dose 1.2 Post Dose 1.5 Post	Time Dos	e Given		NB: S	Should be Taken at Time Point Zer					
2 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5	Post Dose 2 Post Dose 15 Post Dose 3 Post Dose 2 Post Dose 3 Post Dose 2 Post Dose 3 Post Dose 3 Post Dose 4 Post Dose 5 Post Dose 6 Post Dose 6 Post Dose 12										
Post Dose 4 Post Dose 3 Post Dose 4 Post Dose 6 Post Dose 6 Post Dose 8 Post Dose 12] Post D	Post Dose 4 Post Dose 3 Post Dose 4 Post Dose 4 Post Dose 4 Post Dose 4 Post Dose 6 Post Dose 12] Post Dose	2		0.5	I			Post Dose	2	PostDose	
Post Dose 6 Post Dose 12 Post	Post Dose 6 Post Dose 8 Post Dose 6 Post Dose 12 P	-+			\longrightarrow						
Post Dose 8 Post Dose 6 Post Dose 8 Post Dose 9 Post Dose 8 Post Dose 8 Post Dose 9 Post Dose 8 Post Dose 9 Post Dose 8 Post Post Post Post Post Post Post Post	Post Dose 8 Post Dose 6 Post Dose 6 Post Dose 6 Post Dose 8 Post Dose 12	3		1.0	I						
Post Dose 12 Post Dose 13 Post Dose	Post Dose 12 Post Dose 12 Post Dose 13 Post Dose										
Fost Dose 18 Fost Dose 12	Fost Dose 18] Post Dose 12] Trough 24 Samples should be sent altouether with this Request Form and TAKEN directly to the Lestie Laboratory, Ground Floor of the Renal Building, Do NOT send to NWLP Specimen Reception. It same on trace-level and any of collection they should be stored refrigered to a renor trace-level and any of collection they should be stored refrigered to a graph of the samples were taken as a Structured Note with petition for record entitled "Tacrotion bey hord to be stored refrigered to a graph of the samples were taken as a Structured Note with petition for record entitled "Tacrotion bey hord to be stored refrigered to a graph of disease by p., time record entitled "Tacrotion beyoned by the date the samples were taken as a Structured Note with petition for control of the profile results will be available on Cerner as a Structured Note with petition and graph of the samples were taken as a structured Note with petition for the profile results will be available on Cerner as a Structured Note with petition 2007 the date of the samples were taken as a structured Note with petition 2007 the date of the samples were taken as a structured Note with petition 2007 the date of the samples were taken as a structured Note with petition 2007 the date of the samples were taken as a structured Note with petition 2007 the date of the samples were taken as a structured Note with petition 2007 the date of the samples were taken as a structured Note with petition 2007 the date of the samples were taken as a structured Note with petition 2007 the date of the samples were taken as a structured Note with petition 2007 the date of the samples were taken as a structured Note with petition 2007 the samples were taken as a structured Note with petition 2007 the date of the samples were taken as a structured Note with petition 2007 the samples were taken as a structured Note with petition 2007 the samples were taken as a structured Note with petition 2007 the samples were taken as a structured Note with petition 200	4		1 5**							
Trough 24 Samples should be sent <u>attragether</u> with this Request Form and TAKEN directly to the Leslie Laboratory, Ground Floor of the Renal Building, BO NOT send to NWLP Specimen Reception. If sar are not received on the day of collection they should be stored refrigerated. Agraphical representation of the profile results will be available on Cerner as a Structured Note with pointer record entitled Tear-critique Profile* followed by the date the samples were taken e.g., Tear-Profile 260121. Agraphical representation on the profile results will be available on Cerner as a Structured Note with pointer record entitled Tear-critique Profile* followed by the date the samples were taken e.g., Tear-Profile 260121. Agraphical representation on the profile* belowed by the date the samples were taken e.g., Tear-Profile 260121. Please Note: Numerous variables determine the target drug levels e.g. great or disease byte, time transplant, clinical and great function, co-medication, drug formulation, which should be taken consideration when interpreting results. Please direct any queries to the Leslie Brent Laboratory on Ext 36637 or 36842. Please direct any queries to the Leslie Brent Laboratory on Ext 36637 or 36842. **Solver of Laboratory on Ext 36637 or 36842.** **Please direct any queries to the Leslie Brent Laboratory on Ext 36637 or 36842.** **Solver of Laboratory on Ext 36637 or 3	Trough 24 Samples should be sent <u>attogether</u> with this Request Form and TAKEN directly to the Leslie Laboratory, Ground Floor of the Renal Building, BO NOT send to NWLP Specimen Reception. If sail are not received on the day of collection they should be store of refrigerated. A graphical enter representation on the profile results will be available on Cerner as a Structured Note with potent record entitled? acroinus Profile* followed by the date the samples were taken e.g., Tecne Profile 260121. Please Note with unerous variables determine the target drug levels e.g., graft or disease type, time transplant, clinical and graft function, co-medication, drug formulation, which should be taken consideration when interpreting results. Please direct any queries to the Leslie Brent Laboratory on Ext 36637 or 36842. Please direct any queries to the Leslie Brent Laboratory on Ext 36637 or 36842. **Not required for Advagrafferwarus/Calliptor** **Not requ	*		1.5**	- 1			Post Dose	18]		
Samples should be sent attacether with this Request Form and TAKEN directly to the Lestie Laboratory, Ground Floor of the Renal Eulalog DAO NOT send to NNU? Specimen Reception, If sar are not received on the day of collection they should be stored retrigerated. 4.0 4.0 4.0 4.0 4.0 4.0 4.0 5.0 6.0 9.0 6.0 9.0 6.0 10	Samples should be sent altouether with its Request Form and TAKEN directly to the Lestie Eaboratory, Cronund Floor of the Reveal Euborate Building Bo Mo 15 read to NIVE/Decimen Reception, Its are not received on the day of collection they should be stored retrigerated. A graphical representation of the profile results will be available on Cerner as a Structured Note with potential representation on the profile results will be available on Cerner as a Structured Note with potential representation on the profile results will be available on Cerner as a Structured Note with potential record entitled Tacrolinus Profile* followed by the date the samples were taken e.g Tacro Profile 260121. Please Note: Numerous variables determine the target drug levels e.g., graft or disease type, time transplant, clinical and graft function, co-medication, drug formulation, which should be taken consideration when interpreting results. Please Office Numerous variables determine the target drug levels e.g., graft or disease type, time transplant, clinical and graft function, co-medication, drug formulation, which should be taken consideration when interpreting results. Please direct any queries to the Lesile Brent Laboratory on Ext 36837 or 38842. Please Interest to the Lesile Brent Laboratory on Ext 36837 or 38842. **Softered - LBUserie fierol Laboratory on Ext 36837 or 38842.** **Softered - LBUserie fierol Laboratory on Ext 36837 or 38842.** **Softered - LBUserie fierol Laboratory on Ext 36837 or 38842.** **Softered - LBUserie fierol Laboratory on Ext 36837 or 38842.** **Softered - LBUserie fierol Laboratory on Ext 36837 or 38842.** **Softered - LBUserie fierol Laboratory on Ext 36837 or 38842.** **Softered - LBUserie fierol Laboratory on Ext 36837 or 38842.** **Softered - LBUserie fierol Laboratory on Ext 36837 or 38842.** **Softered - LBUserie fierol Laboratory on Ext 36837 or 38842.** **Softered - LBUserie fierol Laboratory on Ext 36837 or 38842.** **Softered - LBUserie fierol Laboratory on Ext 36837 or 38842	_								,	•
are not received on the day of collection they should be stored retrigerated. A graphical representation of the profile results will be available on Cerner as a Structured Note with patients received and the day of collection they should be stored retrigerated. A graphical representation of the profile results will be available on Cerner as a Structured Note with patients received and the day of collection they should be stored retrigerated. A graphical representation of the profile results will be available on Cerner as a Structured Note with patients received and the day of collection they should be stored retrigerated. A graphical representation of the profile results will be available on Cerner as a Structured Note with patients received and the day of collection they should be stored retrigerated. A graphical representation of the profile results will be available on Cerner as a Structured Note with patients received and the day of collection they should be stored retrigerated. A graphical representation of the profile results will be available on Cerner as a Structured Note with patients received and the profile results of collection that they are stored in the day of collection they should be stored retrigerated. A graphical representation of the profile results for collection they available on Cerner as a Structured Note with patients and profile results and collection of the profile results and coll	are not received on the day of collection they should be stored refrigerated. A graphical representation of the profile results will be available on Cerner as a Structured Note with patients record entitled "Tacrolinus Profile" followed by the date the samples were taken e.g., Tacrolinus Profile" followed by the date the samples were taken e.g., Tacrolinus Profile" followed by the date the samples were taken e.g., Tacrolinus Profile" followed by the date the samples were taken e.g., Tacrolinus Profile" followed by the date the samples were taken e.g., Tacrolinus Profile" followed by the date the samples were taken e.g., Tacrolinus Profile" followed by the date the samples were taken e.g., Tacrolinus Profile" followed by the date the samples were taken e.g., Tacrolinus Profile" followed by the date the samples were taken e.g., Tacrolinus Profile" followed by the date the samples were taken e.g., Tacrolinus Profile" followed by the date the samples were taken e.g., Tacrolinus Profile" followed by the date the samples were taken e.g., Tacrolinus Profile" followed by the date the samples were taken e.g., Tacrolinus Profile" followed by the date the samples were taken e.g., Tacrolinus Profile" followed by the date the samples were taken e.g., Tacrolinus Profile" followed by the date the samples were taken e.g., Tacrolinus Profile followed by the date the samples were taken e.g., Tacrolinus Profile followed by the date the samples were taken e.g., Tacrolinus Profile followed by the date the samples were taken e.g., Tacrolinus Profile followed by the date the samples were taken e.g., Tacrolinus Profile followed by the date the samples were taken e.g., Tacrolinus Profile followed by the date the samples were taken e.g., Tacrolinus Profile followed by the date the samples were taken e.g., Tacrolinus Profile followed by the date the samples were taken e.g., Tacrolinus Profile followed by the date the samples were taken e.g., Tacrolinus Profile followed by the date taken e.g., tacrolinus Profile followed by the date take	5		2.0			_ II s	amples should be sent all	together with this Red	quest Form and TAKEN	directly to the Leslie
patient's record entitled "Tacrolimus Profile" followed by the date the samples were taken e.g. Tacro Profile 250121. Please Note: Numerous variables determine the target drug levels e.g., graft or disease type, time transplant, clinical and graft. function, co-medication, drug formulation, which should be taken on side action when interestion	## 10 6.0 9 8.0 10 (12.0) 11 (18.0)*** NB: Time points in ")" are additional time points where in-patients maybe monitored "Not required for Advagard Financian Code. A Request from situation about the second source and the s	6		3.0							cililetti Neceptioti : Itsai
Police 200121. Please Note: Numerous variables determine the target drug levels e.g., graft or disease type, time transplant, clinical and graft function, co-medication, drug formulation, which should be taken on solder at the consideration when interpreting results. Please Note: Numerous variables determine the target drug levels e.g., graft or disease type, time transplant, clinical and graft function, co-medication, drug formulation, which should be taken on solder at the consideration when interpreting results. Please Note: Numerous variables determine the target drug levels e.g., graft or disease type, time transplant, clinical and graft function, co-medication, drug formulation, which should be taken on solder at the consideration when interpreting results. Please Note: Numerous variables determine the target drug levels e.g., graft or disease type, time transplant, clinical and graft function, co-medication, drug formulation, which should be taken on solder at the consideration when interpreting results. Please Note: Numerous variables determine the target drug levels e.g., graft or disease type, time transplant, clinical and graft function, co-medication, drug formulation, which should be taken on solder and preting and p	Please Note: Numerous variables determine the target drug levels e.g., graft or disease type, time transplant, clinical and graft shundion, co-medication, drug formulation, which should be taken on solid entire transplant, clinical and graft shundion, co-medication, drug formulation, which should be taken on solid entire transplant, clinical and graft shundion, co-medication, drug formulation, which should be taken on solid entire transplant, clinical and graft shundion, co-medication, drug formulation, which should be taken on solid entire transplant, clinical and graft shundion and graft shundion, co-medication, drug formulation, which should be taken on solid entire transplant, clinical and graft shundion and graft shundion, co-medication, drug formulation, which should be taken on solid entire transplant, clinical and graft shundion and graft shundion, co-medication, drug formulation, which should be taken on solid entire transplant, clinical and graft shundion, co-medication, drug formulation, which should be taken on solid entire transplant, clinical and graft shundion and graft shundion, co-medication, drug formulation, which should be taken on solid entire transplant, clinical and graft shundion, co-medication, drug formulation, which should be taken on when interpreting results. Please forter Numerous variables determine the target drug formulation, which should be taken on solid entire transplant, clinical and graft shundion, co-medication, drug formulation, which should be taken on when interpreting results. Please forter Numerous variables determine the target drug formulation, which should be taken on when interpreting results. Please forter Numerous variables determine the target drug forter transplant, clinical and graft shundion, co-medication, drug forter transplant, clinical and graft shundion. Please forter Numerous variables determine the target formulation and shundion. Please forter Numerous variables determine the target formulation and shundion. Please forter Numerous variables dru	7		4.0			A	graphical representation o	fthe profile results will	be available on Cerner as	a Structured Note with
Please Note: Numerous variables determine the target drug levels e.g. graat or disease type, time transplant, clinical and graft function, co-nedication, drug formulation, which should be taken on sideration when interpreting results. Please direct any queries to the Leslie Brent Laboratory on Ext 36637 or 36642. Please direct any queries to the Leslie Brent Laboratory on Ext 36637 or 36642. Please direct any queries to the Leslie Brent Laboratory on Ext 36637 or 36642. Please direct any queries to the Leslie Brent Laboratory on Ext 36637 or 36642. Please direct any queries to the Leslie Brent Laboratory on Ext 36637 or 36642. Please direct any queries to the Leslie Brent Laboratory on Ext 36637 or 36642. Please direct any queries to the Leslie Brent Laboratory on Ext 36637 or 36642. Please direct any queries to the Leslie Brent Laboratory on Ext 36637 or 36642. Please direct any queries to the Leslie Brent Laboratory on Ext 36637 or 36642. Please direct any queries to the Leslie Brent Laboratory on Ext 36637 or 36642. Please direct any queries to the Leslie Brent Laboratory on Ext 36637 or 36642. Please direct any queries to the Leslie Brent Laboratory on Ext 36637 or 36642. Please direct any queries to the Leslie Brent Laboratory on Ext 36637 or 36642. Please direct any queries to the Leslie Brent Laboratory on Ext 36637 or 36642. Please direct any queries to the Leslie Brent Laboratory on Ext 36637 or 36642. Please direct any queries to the Leslie Brent Laboratory on Ext 36637 or 36642. Please direct any queries to the Leslie Brent Laboratory on Ext 36637 or 36642. Please direct any queries to the Leslie Brent Laboratory on Ext 36637 or 36642. Please direct any queries to the Leslie Brent Laboratory on Ext 36637 or 36642. Please direct any queries to the Leslie Brent Laboratory on Ext 36637 or 36642. Please direct any queries to the Leslie Brent Laboratory on Ext 36637 or 36642. Please direct any queries to the Leslie Brent Laboratory on Ext 36637 or 36642. Please direct any queries to	Please Note: Numerous variables determine the target drug levels e.g., graft or disease type, time transplant, clinical and graft function, co-medication, drug formulation, which should be taken consideration when interpreting results. Please Mote: Numerous variables determine the target drug levels e.g., graft or disease type, time transplant, clinical and graft function, co-medication, drug formulation, which should be taken consideration when interpreting results. Please direct any queries to the Leslie Brent Laboratory on Ext 36837 or 36842. Please direct any queries to the Leslie Brent Laboratory on Ext 36837 or 36842. Please direct any queries to the Leslie Brent Laboratory on Ext 36837 or 36842. Please direct any queries to the Leslie Brent Laboratory on Ext 36837 or 36842. Please direct any queries to the Leslie Brent Laboratory on Ext 36837 or 36842. Please direct any queries to the Leslie Brent Laboratory on Ext 36837 or 36842. Please direct any queries to the Leslie Brent Laboratory on Ext 36837 or 36842. Please direct any queries to the Leslie Brent Laboratory on Ext 36837 or 36842. Please direct any queries to the Leslie Brent Laboratory on Ext 36837 or 36842. Please direct any queries to the Leslie Brent Laboratory on Ext 36837 or 36842. Please direct any queries to the Leslie Brent Laboratory on Ext 36837 or 36842. Please direct any queries to the Leslie Brent Laboratory on Ext 36837 or 36842. Please direct any queries to the Leslie Brent Laboratory on Ext 36837 or 36842. Please direct any queries to the Leslie Brent Laboratory on Ext 36837 or 36842. Please direct any queries to the Leslie Brent Laboratory on Ext 36837 or 36842. Please direct any queries to the Leslie Brent Laboratory on Ext 36837 or 36842. Please direct any queries to the Leslie Brent Laboratory on Ext 36837 or 36842. Please direct any queries to the Leslie Brent Laboratory on Ext 36837 or 36842. Please direct any queries to the Leslie Brent Laboratory on Ext 36837 or 36842. Please direct any queries to the	'		4.0					rolimus Profile" followe	ed by the date the samples	s were taken e.g. Tacro
9 8.0 (12.0) 10 (12.0) 11 (18.0)*** 12 24.0 *** NB: Time points in "[] are additional time points where in-patients may be monitored "I Not required for Advagra/Envarsus/Dailiport "I Not required for Prograf/Adoport I Not required from Advagra/Envarsus/Dailiport "I Not required from Request Form & Patientic Birth Labout-Printmation Sheet-Niter Outse & Request Forms/IBL Request Forms/	9 8.0 (12.0) 10 (12.0) 11 (18.0)*** 12 24.0 *** NB: Time points in "[]" are additional time points where in-patients may be monitored "If Not required for Advagra/Envarsus/Dailiport "If Not required for Prograf/Adoport Industries literal Laboratory Billiport "If Not required for Prograf/Adoport Industries literal Laboratory Billiport "If Not required for Prograf/Adoport Industries literal Laboratory Billiport "If Not required for Prograf/Adoport Industries literal Laboratory Billiport "If Not required for Prograf/Adoport Industries literal Laboratory Billiport "If Not required for Prograf/Adoport Industries literal Laboratory Billiport "If Not required for Prograf/Adoport Industries Billiport Billiport "If Not required for Prograf/Adoport Industries Billiport Bi	8		6.0			P	ease Note: Numerous var			
10 (18.0)	10 (18.0)	9		8.0			tri co	ansplant, clinical and gra onsideration when interpret	ft function, co-medica ingresults.	ation, drug formulation, v	which should be taker
NB: Time points in "()" are additional time points where in-patients may be monitored **Not required for Advagra/Rehvarsus/Dailiport **Y Not required for Progra/Adoport Rend - LBLMzelle Bren LabioLPrinomaton Sheetiviser Outer & Request Forms/Tbcoolinus Brug Profile Request Form & Peructions Both usbook	NB: Time points in "()" are additional time points where in-patients may be monitored **Not required for Advagra//Envirous/Dailipon **Y Not required for Progra//Adoport Rend - LBLMzelle Bren LabioLPrinomation Sheet/Niser Outer & Request Forms/Tbcoolinus Brug Profile Request Form & Peructions BCH 1985/Process	10		(12.0)			T II P	ease direct any queries to	the Leslie Brent Labora	atory on Ext 36637 or 366	42.
NB: Time points in "()" are additional time points where in-patients may be monitored Not required for Advagra/Remarks/Dailipon **Not required for Progra/Redoport Rend -LBUkesile Brini Lab/OLP/Information Sheet/viser Outer & Request Forms/Tiborolinus Brug Profile Request Form & Peruscince BOTH signory **Peruscince BOTH signory **Authorized By: Jame Lite** **Date Install Lite** **D	NB: Time points in "()" are additional time points where in-patients may be monitored Not required for Advagra//Evarsus/Dailipon **Not required for Progra//Adoport Rend -LBUAzelle Bern Lab/OLP/information Sheet/Alser Outer & Request Forms/Tboolinus Brug Profile Request Form & Peruschore BOTH selection	11		(18 N)¥¥							
NB: Time points in "[]" are additional time points where in-patients may be monitored. ** Not required for Advagra/Envarsus/Dailiport. ** Not required for Progra/Adoport. **Not required for Progra/Adoport. **Not required for Progra/Adoport. **Not required for Advagra/Envarsus/Dailiport. **Not required for Progra/Adoport. **SARred - LBL\Lestie literal LabYoLPihotmailon. Sheelables Code & Request Format\BL. Request Format\	NB: Time points in "[]" are additional time points where in-patients may be monitored. ** Not required for Advagra/Envarsus/Dailiport. ** Not required for Progra/Adoport. **Not required for Progra/Adoport. **Not required for Progra/Adoport. **Not required for Advagra/Envarsus/Dailiport. **Not required for Progra/Adoport. **SARend - LBLitarile firm Lab/OLP/Hotmailon Sheebilder Oute & Request Format But Request Format But Social States and Social States			· ,							
**Not required for Advagraf/Forwarsus/Dailipot **Y Not required for Prograf/Adoport Sternd - LBILLesile Breni Lab/OLP/Information Sterebister Outde & Request Formatible. Request Formatible Date is used: 140H-20223 Sternd - LBILLesile Breni Lab/OLP/Information Sterebister Outde & Request Formatible Date is used: 140H-20223 Sternd - LBILLesile Breni Lab/OLP/Information Sheebister Outde & Request Formatible Date is used: 140H-20223 Sternd - LBILLesile Breni Lab/OLP/Information Sheebister Outde & Request Formatible Date is used: 140H-20223 Sternd - LBILLesile Breni Lab/OLP/Information Sheebister Outde & Request Formatible Date is used: 140H-20223 Sternd - LBILLesile Breni Lab/OLP/Information Sheebister Outde & Request Formatible Date is used: 140H-20223 Sternd - LBILLesile Breni Lab/OLP/Information Sheebister Outde & Request Formatible Date is used: 140H-20223 Sternd - LBILLesile Breni Lab/OLP/Information Sheebister Outde & Request Formatible Date is used: 140H-20223 Sternd - LBILLesile Breni Lab/OLP/Information Sheebister Outde & Request Formatible Date is used: 140H-20223 Sternd - LBILLesile Breni Lab/OLP/Information Sheebister Outde & Request Formatible Date is used: 140H-20223 Sternd - LBILLesile Breni Lab/OLP/Information Sheebister Outde & Request Formatible Date is used: 140H-20223 Sternd - LBILLesile Breni Lab/OLP/Information Sheebister Outde & Request Formatible Date is used: 140H-20223 Sternd - LBILLesile Breni Lab/OLP/Information Sheebister Outde & Request Formatible Date is used: 140H-20223 Sternd - LBILLesile Breni Lab/OLP/Information Sheebister Outde & Request Formatible Date is used: 140H-20223 Sternd - LBILLesile Breni Lab/OLP/Information Sheebister Outde & Request Formatible Date is used: 140H-20223 Sternd - LBILLesile Breni Lab/OLP/Information Sheebister Outde & Request Formatible Date is used: 140H-20223 Sternd - LBILLesile Breni Lab/OLP/Information Sheebister Outde & Request Formatible Date is used: 140H-20223 Sternd - LBILLesile Breni Lab/OLP/Information Sheebister Outde & Requ	**Not required for Advagraf/Forvarsus/Dailipot **V*Not required for Prograf/Adoport Sternet - LBILLestile Breni Lab/OLP/Information Street/Sternet Grows Request Forms/SBL Re										
GMS index Ko.: BD11 Authorized By:time Lite Date levided: 14GAZZZZZZZZZZZZZZZZZZZZZZZZZZZZZZZZZZZZ	GMS index No.: 8011 Authorized By Jame Lize Base Industrial Conference of the Secretary of	** N	B: Time points in lot required for A	ı "()" are addıtıor Advagraf/Envarsu	nai time points where in is/Dailiport ^{YY} Not r	-patients may be monitored required for Prograf/Adoport	Ш				
*tolleo	*rolleo	Allegard - 1810 and	le Breni LabiGLP\into	Ins	fuctions E011 u6.docs		8.		iomation Sheels\liser Guide & R instructions	leques Forms\LBL Reques Forms\Tbo ISB11 u5docx	
Atrolleo.	ontrolleo	The real - retries	o - E011	Authorises	d By: Jane I Lee	Dale Bsued:1404/2023	- 11	QIIIS Index No.: ISD11	Authorised By: Jan	nel Lee	Dale Bsued: 1404/2023
Atrolle Control of the Control of th	ONITO										
						01					
						S					
					6	(C)					
		QM⊖ Index M			101	S					
		QM⊖ Index M		900	uol						
		QM⊖ Index M		,or	uol						
		QM⊖ Index M		,or	uol						
Jncoin Lands		QM⊖ Index M									